Literature DB >> 7857701

In vivo stimulation by tamoxifen of cathepsin D RNA level in breast cancer.

T Maudelonde1, C Escot, P Pujol, P Rouanet, A Defrenne, J P Brouillet, H Rochefort.   

Abstract

We have previously shown that 3 weeks of treatment with tamoxifen, of patients with primary breast carcinomas, increased cytosolic cathepsin D protein in oestrogen receptor (ER) positive tumours [Maudelonde et al., Cancer 1989, 63, 1265-1270]. In order to investigate the mechanism of this increase and to eliminate a transient flare-up effect, we semi-quantified cathepsin D RNA levels by in situ hybridisation in 32 breast carcinomas from patients treated with tamoxifen for 3 weeks prior to surgery and in 35 breast cancer patients receiving no tamoxifen. We found that tamoxifen increased cathepsin D RNA level regardless of the ER status of the tumours. In ER positive tumours, tamoxifen increased the cathepsin D RNA level to the same extent as cytosolic cathepsin D protein but not in ER negative tumours. The induction of cathepsin D RNA by tamoxifen in ER positive tumours was probably due to its agonist activity, also observed in vitro in breast cancer cell lines. These results suggest that the cathepsin D gene is inducible by oestrogens in ER positive breast cancer as it is in breast cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7857701     DOI: 10.1016/0959-8049(94)00343-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

1.  Tamoxifen inhibits acidification in cells independent of the estrogen receptor.

Authors:  N Altan; Y Chen; M Schindler; S M Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

2.  Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Regulation by 17beta-estradiol, tamoxifen and ICI 182,780.

Authors:  D Couissi; V Dubois; C Remacle; E Schonne; A Trouet
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

3.  Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer.

Authors:  C Escot; Y Zhao; C Puech; H Rochefort
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: lack of association with clinical outcome.

Authors:  G Ferrandina; G Scambia; A Fagotti; G D'Agostino; P Benedetti Panici; A Carbone; S Mancuso
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

5.  Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.

Authors:  P Pujol; J P Daurès; J P Brouillet; T Maudelonde; H Rochefort; J Grenier
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.